SCHEMBL171869

SCHEMBL171869

C[N+]1(C)CCCC1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.65
TSHR P16473 1/20 0.65
KMT2A Q03164 1/20 0.65
CHRM2 P08172 7/20 0.31
CHRM5 P08912 3/20 0.31
CHRM1 P11229 2/20 0.31
CHRM4 P08173 1/20 0.30
CHRM3 P20309 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL578113 1.00 MEN1 (0.65) MEN1TSHRKMT2ACHRM2CHRM5
SCHEMBL232820 1.00 MEN1 (0.65) MEN1TSHRKMT2ACHRM2CHRM5
Hydrochloric Acid SCHEMBL15819856 0.98 MEN1 (0.63) MEN1TSHRKMT2ACHRM2CHRM5
Hydrochloric Acid SCHEMBL17255832 0.98 MEN1 (0.63) MEN1TSHRKMT2ACHRM2CHRM5
Water SCHEMBL8812670 0.98 MEN1 (0.63) MEN1TSHRKMT2ACHRM2CHRM5
SCHEMBL13113200 0.93 MEN1 (0.57) MEN1TSHRKMT2A
SCHEMBL15189362 0.81 MEN1 (0.65) MEN1TSHRKMT2ACHRM2CHRM5
SCHEMBL30819241 0.79 MEN1 (1.00) MEN1TSHRKMT2ACHRM2CHRM5
SCHEMBL1852325 0.79 MEN1 (1.00) MEN1TSHRKMT2ACHRM2CHRM5
Hydrochloric Acid SCHEMBL1340043 0.77 MEN1 (0.96) MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4679086-A1 BIOMARKER AND USE THEREOF MEIJI CO., LTD (JP) 2026-01-14 EP claimed
US-20250341515-A1 METABOLOMIC BIOMARKERS FOR ACUTE KIDNEY INJURY, ASSAYS, COMPOSITIONS AND METHODS OF USE THEREOF WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2025-11-06 US claimed
CN-117805280-A Ultrahigh performance liquid-mass spectrometry detection method for internal and external components of classical Ming Fang Xiaoxiangqi decoction 陕西省中医药研究院 2024-04-02 CN claimed
CN-117388421-A Method for identifying forage grass rhizosphere secretion and differential metabolite thereof based on non-targeted metabonomics 中国农业大学 2024-01-12 CN claimed
EP-4679086-A1 BIOMARKER AND USE THEREOF MEIJI CO., LTD (JP) 2026-01-14 EP disclosed
US-20250362309-A1 BIOMARKERS AND USE THEREOF FOR DIAGNOSIS, PREVENTION, AND TREATMENT OF MUSCLE ATROPHY MYOMAR MOLECULAR INC. (CA) 2025-11-27 US disclosed
US-20250341515-A1 METABOLOMIC BIOMARKERS FOR ACUTE KIDNEY INJURY, ASSAYS, COMPOSITIONS AND METHODS OF USE THEREOF WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2025-11-06 US disclosed
US-20240376073-A1 QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2024-11-14 US disclosed
US-12016949-B2 Virus IOSBIO LTD (GB) 2024-06-25 US disclosed
CN-117805280-A Ultrahigh performance liquid-mass spectrometry detection method for internal and external components of classical Ming Fang Xiaoxiangqi decoction 陕西省中医药研究院 2024-04-02 CN disclosed
CN-117388421-A Method for identifying forage grass rhizosphere secretion and differential metabolite thereof based on non-targeted metabonomics 中国农业大学 2024-01-12 CN disclosed
CN-115389756-B Detection kit for predicting risk of atrial fibrillation and application thereof 首都医科大学附属北京安贞医院 2023-02-17 CN disclosed
US-20090092913-A1 ADDITIVE CONTAINING PHOTOGENERATING LAYER PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-04-09 US disclosed
US-20090092913-A1 ADDITIVE CONTAINING PHOTOGENERATING LAYER PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-04-09 US disclosed
US-20090092909-A1 CHARGE TRAPPING RELEASER CONTAINING PHOTOGENERATING LAYER PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-04-09 US disclosed
US-20090092915-A1 PHOSPHONIUM CONTAINING CHARGE TRANSPORT LAYER PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-04-09 US disclosed
EP-0647133-A4 COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY. AFFYMAX TECH NV (AN) 1997-10-29 EP disclosed
US-5607691-A IONTOPHORESIS AFFYMAX TECHNOLOGIES N.V. (GB) 1997-03-04 US disclosed
EP-0647133-A1 COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY AFFYMAX TECHNOLOGIES N.V. (AN) 1995-04-12 EP disclosed
WO-1993025197-A1 COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY AFFYMAX TECHNOLOGIES N.V. (AN) 1993-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016949-B2 Virus HAVCR2, TSG101, TMEM205 MEN1 3838/4885TSHR 4408/4885KMT2A 3872/4885
US-20240376073-A1 QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS CFTR, HRH1, HRH4 MEN1 557/4885TSHR 648/4885KMT2A 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.